00
007460.KO Aprogen KIC Inc
- Market cap
- KRW 38.9B
- P/E
- -
- P/B
- 0.67x
- ROE
- -143.3%
- Dividend yield
- 0.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 007460.KO undervalued?
Graham numberThe Graham number of Aprogen KIC Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aprogen KIC Inc fundamental analysis
No fundamental analysis for Aprogen KIC Inc yet.
Aprogen KIC Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aprogen KIC Inc
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment bui…
Full company profileAprogen KIC Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aprogen KIC Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 54.8B | 44.9B | 51.0B | 78.2B | 127B | 141B | 78.3B | 151B | 150B | 118B | 144B |
| Gross Profit | 9.94B | 4.30B | 9.18B | 19.4B | 34.5B | 31.3B | 6.15B | 35.8B | 34.9B | 33.2B | 37.7B |
| Operating Income | 5.06B | 1.83B | 1.57B | 2.57B | 3.97B | -2.67B | -114B | -88.9B | -86.8B | -95.6B | -86.1B |
| EBITDA | - | 4.92B | 741M | 29.3B | -29.6B | 6.50B | -77.3B | -65.5B | -73.4B | -114B | -103B |
| Net Income | 2.41B | 2.34B | -32.1B | 11.7B | -46.5B | -18.0B | -98.7B | -55.6B | -58.1B | -70.2B | -86.8B |
| EPS | - | 47 | -349 | 76 | -254 | -90 | -424 | -228 | -3,073 | -3,411 | -4,125 |
| Balance Sheet | |||||||||||
| Total Assets | 78.6B | 267B | 395B | 654B | 834B | 824B | 600B | 594B | 610B | 717B | 674B |
| Total Liabilities | 43.3B | 117B | 200B | 127B | 144B | 120B | 139B | 177B | 170B | 259B | 260B |
| Shareholders' Equity | 35.3B | 150B | 196B | 303B | 319B | 336B | 215B | 148B | 159B | 158B | 60.5B |
| Cash & Short-term Investments | 442M | 112B | 59.9B | 71.7B | 96.6B | 62.4B | 43.1B | 35.7B | 37.2B | 45.1B | 37.9B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.73B | 8.07B | -1.49B | -1.12B | 22.5B | -84.7B | -113B | -58.2B | -45.0B | -32.7B | -50.8B |
| Capital Expenditure | 1.33B | 78.3M | 4.04B | 7.85B | 2.58B | 34.4B | 19.6B | 54.9B | 23.1B | 32.2B | 5.51B |
| Free Cash Flow | - | 8.00B | -5.53B | -9.29B | 19.4B | -10.7B | -138B | -113B | -68.1B | -64.9B | -56.3B |
| Ratios | |||||||||||
| ROE | 6.8% | 1.6% | -16.4% | 3.9% | -14.6% | -5.4% | -45.9% | -37.6% | -36.6% | -44.3% | -143.3% |
| ROA | 3.1% | 0.9% | -8.1% | 1.8% | -5.6% | -2.2% | -16.4% | -9.4% | -9.5% | -9.8% | -12.9% |
| Net Profit Margin | 4.4% | 5.2% | -62.9% | 15.0% | -36.6% | -12.7% | -125.9% | -36.9% | -38.7% | -59.5% | -60.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aprogen KIC Inc dividends
- Dividend yield
- 0.00%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2007
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 84.6K | 0.00 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.0667:1 on Apr 14, 2026.
Who owns Aprogen KIC Inc
- Insiders 32.93%
- Institutions 0.05%
- Public & others 67.02%
- Shares outstanding 22.2M
- Free float 13.4M
Aprogen KIC Inc company profile
- Company name
- Aprogen KIC Inc
- Ticker
- 007460.KO
- ISIN
- KR7007460009
- Exchange
- Korea Stock Exchange
- Sector
- Industrials
- Industry
- Machinery
- Employees
- 160
- Fiscal year end
- December
- Address
- Hallasigma valley (Sangdaewon-dong), Seongnam-si, South Korea
- Phone
- 82 31 782 3433
- Website
- aprogen.com
About Aprogen KIC Inc
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 2000 and is based in Seongnam-si, South Korea.
Aprogen KIC Inc management
1- Ki-Cheol LimChief Executive Officer and Director · born 1946